| |
MEN
|
WOMEN
|
|---|
|
Controls N = 10 Mean ± SD
|
Hyperlipemic patients N = 20 Mean ± SD
|
p
|
Controls N = 20 Mean ± SD
|
Hyperlipemic patients N = 20 Mean ± SD
|
p
|
|---|
|
BMI
|
25.91 ± 3.58
|
28.51 ± 2.60
|
0.030
|
25.36 ± 3.72
|
26.73 ± 3.59
|
0.24
|
|
HOMA IR
|
1.685 ± 0.771
|
3.137 ± 1.419
|
0.002
KS
|
1.717 ± 0.893
|
2.694 ± 1.011
|
0.001
KS
|
|
QUICKI
|
0,3596 ± 0,0263
|
0,3266 ± 0,0185
|
0,002
|
0,3603 ± 0,0281
|
0,3332 ± 0,0192
|
0,0007
|
|
Uric acid (mmol/l)
|
270.5 ± 65.4
|
379.9 ± 84.2
|
0.003
|
236.1 ± 67.0
|
270.8 ± 58.9***
|
0.13
|
|
Glycemia (mmol/l)
|
5.31 ± 0.53
|
6.11 ± 0.95
|
0.029
KS
|
5.26 ± 0.42
|
5.85 ± 0.70
|
0.0027
|
|
Insulin (mIU/l)
|
6.96 ± 2.80
|
11.43 ± 4.50
|
0.016
KS
|
7.33 ± 3.80
|
10.27 ± 3.52
|
0.034
KS
|
|
Proinsulin intact (pmol/l)
|
2.68 ± 1.15
|
5.51 ± 2.75
|
0.012
KS
|
2.51 ± 1.76
|
4.49 ± 3.11
|
0.034
KS
|
|
C-peptide (nmol/l)
|
0.66 ± 0.31
|
1.11 ± 0.39
|
0.0148
|
0.75 ± 0.35
|
0.92 ± 0.34
|
0.22KS
|
|
Leptin (ng/ml)
|
3.07 ± 3.38
|
6.21 ± 3.78
|
0.012
KS
|
16.06 ± 13***
|
17.79 ± 5.9**
|
0.17KS
|
|
TNFα (pg/ml)
|
14.2 ± 4.15
|
11.52 ± 2.77
|
0.063KS
|
11.65 ± 6.80
|
12.73 ± 9.15
|
0.43KS
|
|
hFABP (pg/ml)
|
3.86 ± 2.47
|
4.53 ± 1.97
|
0.46
|
3.09 ± 1.80
|
3.79 ± 2.00
|
0.41KS
|
|
ACL-IgG (IU/ml)
|
13.08 ± 6.75
|
19.63 ± 16.9
|
0.57KS
|
12.28 ± 6.38
|
16.35 ± 16.8
|
0.99KS
|
- BMI = body mass index, HOMA IR and QUICKI = homeostatic indexes of insulin resistance (see Methods), TNFα = tumor necrosis factor α, hFABP = heart fraction of fatty acid binding protein, ACL-IgG = IgG anticardiolipin. Other designations are the same as in Table 1.
